(Q39940279)

English

In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae

scientific article published on 7 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae (English)

1 reference

Europe PubMed Central

15 September 2017

Klebsiella pneumoniae

0 references

Escherichia coli

1 reference

based on heuristic

inferred from title

author name string

Akihiro Morinaka

1

1 reference

Europe PubMed Central

15 September 2017

Yuko Tsutsumi

2

1 reference

Europe PubMed Central

15 September 2017

Keiko Yamada

3

1 reference

Europe PubMed Central

15 September 2017

Yoshihiro Takayama

4

1 reference

Europe PubMed Central

15 September 2017

Shiro Sakakibara

5

1 reference

Europe PubMed Central

15 September 2017

Toshihiko Takata

6

1 reference

Europe PubMed Central

15 September 2017

Takao Abe

7

1 reference

Europe PubMed Central

15 September 2017

Takeshi Furuuchi

8

1 reference

Europe PubMed Central

15 September 2017

Seiichi Inamura

9

1 reference

Europe PubMed Central

15 September 2017

Yoshiaki Sakamaki

10

1 reference

Europe PubMed Central

15 September 2017

Nakako Tsujii

11

1 reference

Europe PubMed Central

15 September 2017

Takashi Ida

12

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

7 March 2016

1 reference

Europe PubMed Central

15 September 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

15 September 2017

60

1 reference

Europe PubMed Central

15 September 2017

5

1 reference

Europe PubMed Central

15 September 2017

3001-3006

1 reference

Europe PubMed Central

15 September 2017

OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Proliferation and significance of clinically relevant β-lactamases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Updated functional classification of beta-lactamases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

22 September 2017

Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

25 September 2017

In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

25 September 2017

Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

15 June 2018

Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

20 August 2018

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

20 August 2018

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4862534

20 August 2018

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26953205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/26953205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.02704-15

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39940279&oldid=1879126111"